Rudolph E. Tanzi Headshot
Report a problem with this profile
[email protected]

Rudolph E. Tanzi      

Alzheimer's Disease Researcher; Expert on the Genetics of Neurological Disease; Professor of Neurology at Harvard Medical School

Dr. Rudolph E. Tanzi is the Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, Co-Director of the Henry and Allison McCance Center for Brain Health, and Co-Director of the MassGeneral Institute for Neurodegenerative Disease at Massachusetts General Hospital. He also serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi received a B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School in 1990.

Dr. Tanzi’s groundbreaking discovery of the first Alzheimer’s disease (AD) gene, the amyloid precursor protein (APP) gene, including discovery of the two other early-onset familial AD genes, presenilin 1 and 2 has made him a preeminent global leader in the fight to end Alzheimer’s. Acknowledged by Time Magazine as “one of the Top 10 medical breakthroughs of the year”, Tanzi heads a consortium of researchers at the Cure Alzheimer’s Fund Alzheimer’s Genome Project where he has identified several other AD genes, including ADAM10 and CD33, the first AD gene shown to regulate neuroinflammation. He also discovered the Wilson’s disease gene and contributed to the detection of several other neurological disease genes.

Dr. Tanzi and his team’s innovative approach made scientific history as the first to use human stem cells to create three-dimensional cell culture organoids of AD, dubbed as “Alzheimer’s-in-a-Dish”. This model was the first to recapitulate all three key AD pathological hallmarks in vitro, and first to definitively show that amyloid plaques directly cause neurofibrillary tangles. The 3-D model also made drug screening for AD faster and more cost-effective. Using this system, he has developed several novel therapies for AD including gamma secretase modulators targeting amyloid pathology, ALZT-OP1 targeting neuroinflammation and a neuroprotective drug combination, AMX0035, which was recently successful in a clinical trial of ALS (Lou Gehrig's disease) and now seeking FDA approval. Dr. Tanzi also discovered that beta-amyloid plays a functional role in the brain as an anti-microbial peptide, supporting a role for infection in AD pathology.

Dr. Tanzi serves as Chair of the Cure Alzheimer’s Fund Research Leadership Group and numerous advisory and editorial boards. He has published roughly 600 research papers and has received the highest awards in his field, including the Metropolitan Life Foundation Award, Potamkin Prize, Ronald Reagan Award, Silver Innovator Award, the Smithsonian American Ingenuity Award, and the Brain Research Foundation Award. In 2015, he was named to TIME magazine’s list of TIME100 Most Influential People in the World. He co-authored the books Decoding Darkness, and the three international bestsellers, Super Brain, Super Genes, and The Healing Self, with Dr. Deepak Chopra. Dr. Tanzi has hosted three shows public television, regularly appears on television news programs, has testified to Congress on both Alzheimer’s disease and brain health.

News


Evolution Is Moving Us Away from Selfishness. But Where Is It ...

Renowned medical researcher Dr. Rudolph Tanzi takes you on a tour of the brain , and explains why positive thinking might be the best gift you can give your ...

Prana Alzheimer's disease data features at world leading conference

Professor Rudolph Tanzi presents results from testing PBT2 in the “Alzheimer's in a Dish Model” at the Alzheimer's Association.

Why You Need to Start Meditating on Vacations | MONEY

... isn't strictly psychological; there is a clear and quantifiable change in how our bodies function,” said Harvard researcher Rudolph Tanzi in the news release.

Related Speakers View all


More like Rudolph